In 1997, in attempting to determine whether MAdCAM-1 or its receptor α4β7 was a suitable target for therapeutic intervention in gut-associated inflammation, D’Picarella et al. found that β7- and MAdCAM-1-specific antibodies blocked lymphocyte recruitment to the colon in a colitis model, significantly reducing disease severity. Here, MADCAM1 is linked to colitis.